167 related articles for article (PubMed ID: 37004641)
1. Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis".
Marshall J; Sharma A; Darken P; Ouwens M; Singh B; Tansey-Dwyer D
Adv Ther; 2023 May; 40(5):2549-2555. PubMed ID: 37004641
[No Abstract] [Full Text] [Related]
2. A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis".
Ismaila AS; Haeussler K; Malmenäs M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2023 May; 40(5):2556-2561. PubMed ID: 37004642
[No Abstract] [Full Text] [Related]
3. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China.
Zhou Y; Duan S; Zhang L; Peng F
Respir Med; 2024 May; 226():107632. PubMed ID: 38621548
[TBL] [Abstract][Full Text] [Related]
5. 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study.
Lipson DA; Birk R; Brealey N; Zhu CQ
Adv Ther; 2020 Dec; 37(12):4894-4909. PubMed ID: 33011864
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Mehta R; Farrell C; Hayes S; Birk R; Okour M; Lipson DA
Clin Pharmacokinet; 2020 Jan; 59(1):67-79. PubMed ID: 31321713
[TBL] [Abstract][Full Text] [Related]
7. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Lipson DA; Crim C; Criner GJ; Day NC; Dransfield MT; Halpin DMG; Han MK; Jones CE; Kilbride S; Lange P; Lomas DA; Lettis S; Manchester P; Martin N; Midwinter D; Morris A; Pascoe SJ; Singh D; Wise RA; Martinez FJ
Am J Respir Crit Care Med; 2020 Jun; 201(12):1508-1516. PubMed ID: 32162970
[No Abstract] [Full Text] [Related]
8. Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease.
Parri G; Nieri D; Roggi MA; Vagaggini B; Celi A; Paggiaro P
Expert Rev Respir Med; 2018 Dec; 12(12):997-1005. PubMed ID: 30463451
[No Abstract] [Full Text] [Related]
9. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D
Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
[TBL] [Abstract][Full Text] [Related]
10. Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.
Tabberer M; Jones CE; Kilbride S; Halpin DMG; Lomas DA; Pascoe S; Singh D; Wise RA; Criner GJ; Lange P; Dransfield MT; Han MK; Martinez FJ; Kaisermann MC; Lipson DA
Adv Ther; 2020 Sep; 37(9):3775-3790. PubMed ID: 32647911
[TBL] [Abstract][Full Text] [Related]
11. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
Bardsley S; Criner GJ; Halpin DMG; Han MK; Hanania NA; Hill D; Lange P; Lipson DA; Martinez FJ; Midwinter D; Siler TM; Singh D; Wise RA; van Zyl-Smit RN; Berkman N
Respir Med; 2022 Dec; 205():107040. PubMed ID: 36470149
[TBL] [Abstract][Full Text] [Related]
12. Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
Mannino D; Bogart M; Germain G; Huang SP; Ismaila AS; Laliberté F; Jung Y; MacKnight SD; Stiegler MA; Duh MS
Int J Chron Obstruct Pulmon Dis; 2022; 17():491-504. PubMed ID: 35281476
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).
Zheng J; Zhong N; Wang C; Huang Y; Chen P; Wang L; Hui F; Zhao L; Wang H; Luo L; Du X; Han Goh A; Lipson DA
COPD; 2018; 15(4):334-340. PubMed ID: 30265816
[TBL] [Abstract][Full Text] [Related]
15. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
Bogart M; Bengtson LGS; Johnson MG; Bunner SH; Gronroos NN; DiRocco KK
Int J Chron Obstruct Pulmon Dis; 2024; 19():97-110. PubMed ID: 38226396
[TBL] [Abstract][Full Text] [Related]
16. Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial.
Zheng J; Zhong N; Wang C; Wei LP; Zhou XD; Zhao L; Dong Yuan Y; He B; Wu B; Du X; Song J; Lipson DA
Curr Med Res Opin; 2021 Jan; 37(1):145-155. PubMed ID: 33124900
[TBL] [Abstract][Full Text] [Related]
17. Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
Tabberer M; Lomas DA; Birk R; Brealey N; Zhu CQ; Pascoe S; Locantore N; Lipson DA
Adv Ther; 2018 Jan; 35(1):56-71. PubMed ID: 29313286
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system.
Balmaceda C; Espinoza MA; Abbott T; Peters A
Expert Rev Pharmacoecon Outcomes Res; 2022 Jul; 22(5):743-751. PubMed ID: 35176212
[TBL] [Abstract][Full Text] [Related]
19. Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate/umeclidinium/vilanterol fixed-dose combination in chronic obstructive pulmonary disease.
Calzetta L; Rogliani P
Expert Rev Respir Med; 2023 Dec; 17(12):1273-1283. PubMed ID: 38318884
[TBL] [Abstract][Full Text] [Related]
20. COPD exacerbation costs in the IMPACT study: a within-trial analysis.
Bogart MR; Hopson SD; Shih HC; Stanford RH; Coutinho AD
Am J Manag Care; 2020 May; 26(5):e150-e154. PubMed ID: 32436683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]